Since its founding, immatics has fueled its growing business by partnering with academic institutions, hospitals, consulting companies and other businesses.
At present, the growing pipeline of novel tumor-associated antigens and immunotherapy products identified and developed by immatics offers numerous opportunities for co-development of our product candidates by pharmaceutical and biotech companies.
Biopharmaceutical companies with a focus on oncology and strong interest in the field of clinical development of active immunotherapy are welcome to contact us to find out more about co-development partnership.
